Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMA401 in Painful Diabetic Neuropathy
NCT03297294Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of olodanrigan in diabetic neuropathy, sponsored by Novartis. Started Mar 2018; status: terminated.
02
Drugs
olodanrigan
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT03297294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03297294.